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Background: Research indicates that 3% of people receiving opiate substitution treatment (OST) in the UK manage
to achieve abstinence from all prescribed and illicit drugs within 3 years of commencing treatment, and there is
concern that treatment services have become skilled at engaging people but not at helping them to enter a stage
of recovery and drug abstinence. The National Treatment Agency for Substance Misuse recommends the
involvement of families and wider social networks in supporting drug users’ psychological treatment, and this pilot
randomized controlled trial aims to evaluate the impact of a social network-focused intervention for patients
receiving OST.
Methods and design: In this two-site, early phase, randomized controlled trial, a total of 120 patients receiving
OST will be recruited and randomized to receive one of three treatments: 1) Brief Social Behavior and Network
Therapy (B-SBNT), 2) Personal Goal Setting (PGS) or 3) treatment as usual. Randomization will take place following
baseline assessment. Participants allocated to receive B-SBNT or PGS will continue to receive the same treatment
that is routinely provided by drug treatment services, plus four additional sessions of either intervention. Outcomes
will be assessed at baseline, 3 and 12 months. The primary outcome will be assessment of illicit heroin use,
measured by both urinary analysis and self-report. Secondary outcomes involve assessment of dependence,
psychological symptoms, social satisfaction, motivation to change, quality of life and therapeutic engagement.
Family members (n = 120) of patients involved in the trial will also be assessed to measure the level of symptoms,
coping and the impact of the addiction problem on the family member at baseline, 3 and 12 months.
Discussion: This study will provide experimental data regarding the feasibility and efficacy of implementing a social
network intervention within routine drug treatment services in the UK National Health Service. The study will
explore the impact of the intervention on both patients receiving drug treatment and their family members.
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There are estimated to be 306,100 users of heroin or
crack cocaine in the UK [1]. There has been a large in-
crease in investment in the management of drug de-
pendence in the past 10 years, with the number of
people in contact with treatment services in England
doubling between 1998 and 2005 [2]. A key driver for
this increase in provision has been a desire to reduce
criminal activity, but there is now concern that treat-
ment services have become skilled at engaging people
but not at helping them to change their problematic be-
haviors and enter a stage of ‘recovery’ [3]. For example,
research in Scotland found that 3% of people in opiate
substitution treatment (OST) manage to achieve abstin-
ence from all prescribed and illicit drugs within 3 years
of commencing treatment [4]. In particular, there is
concern that effective psychosocial interventions are not
delivered to this population and previous attempts to de-
velop the UK evidence base have not been successful [5].
Opioid-dependent patients receiving methadone often
spend much of their time in social environments that
support and directly reinforce drug use and behaviors
that convey considerable risk of harm to self and others
[6-9]. Patients are routinely advised to abandon their
drug-using supports without having meaningful alterna-
tive social networks in place, and this typically results in
the individual remaining entrenched in existing social
networks. One goal of treatment interventions may be
to help patients transform social networks that support
drug use into those that offer competitive reinforcement
for abstinence. The overall merits of this goal are illus-
trated by a series of studies showing that positive social
supports are associated with a reduced risk of relapse to
heroin and other drug use and with an overall better
treatment response [10-14].
Recent UK policy developments in the drug treatment
field have emphasized the role of families and communi-
ties in recovery from drug use [15,16]. Strategic docu-
ments have pointed to the low numbers of patients
exiting opioid substitution programs drug-free, and the
need to move beyond harm reduction and stabilization
[17]. The National Treatment Agency for Substance
Misuse (NTA) is ‘keen to unlock the potential for fam-
ilies and significant others to play an important support-
ive role in the recovery of individuals through their
greater involvement in treatment where this is appropri-
ate’ (NTA, 2010, page 15) [18]. Despite the available
evidence, current models of drug treatment remain indi-
vidually focused. It is therefore important to evaluate
treatment interventions that may influence the social en-
vironment of drug users in a way that promotes a posi-
tive change in addictive behavior. The intervention
needs to be feasible in routine United Kingdom National
Health Service (NHS) practice and accepted by bothservice users and members of the clinical staff team. It
also needs to impact on patients’ social networks in the
way that research suggests can aid positive change in
drug use and the pursuit of recovery (that is, abstin-
ence from drugs, mental and physical health, and
citizenship [19]).
Social Behavior and Network Therapy (SBNT) is an
intervention developed in the UK. It integrates effective
strategies from other treatment approaches and is built
upon the premise that social network support for change
is central to the resolution of addictive behavior [20].
The intervention facilitates the involvement of close
friends and family as part of the treatment process to
promote substance use change. The approach was ini-
tially targeted at alcohol problems, and was shown to be
as effective and cost-effective as Motivational Enhance-
ment Therapy in the large UK Alcohol Treatment Trial
(UKATT) [21,22]. SBNT has since been adapted for use
with primary heroin users. Twenty therapists from com-
munity drug services in Birmingham were trained to de-
liver the intervention, supported by a treatment manual
and a 2-day workshop followed by video supervision.
Twelve therapists delivered SBNT to 24 patients, and 3-
month outcomes were measured using both quantitative
and qualitative methods. The results suggested that it
was feasible to train therapists to deliver SBNT, with the
participating patients reporting a reduction in drug use
and improved family and social relationships [23].
SBNT was initially developed to be delivered over
eight sessions, although evaluation showed that the ac-
tual number of sessions attended by participants was
fewer than eight, with 64% of the UKATT sample (n =
320) receiving no more than four sessions [24]. Some of
the most important components of the intervention
occur during the early part of the treatment: for
example, drawing a social network map; contacting and
inviting people; reviewing communication and interac-
tions with significant social network members. There-
fore, the intervention will be adapted for the current
study to follow a four-session format, and the treatment
manual used in previous pilot work will be adapted ac-
cordingly [23]. SBNT is therefore hereafter referred to as
Brief Social Behavior and Network Therapy, or B-SBNT.
An important additional area that the present study
aims to explore is the feasibility of recruiting family
members of the patients with drug problems and
assessing the impact of the drug problem on the family
over time. It has been shown that family members living
or in close contact with someone with an addiction
problem suffer high levels of stress symptoms and are
regular visitors to the primary care healthcare system
[25]. To date, there has been no measurement of the po-
tential benefits to family members of interventions fo-
cused on social networks that may include family
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on the drug-related behavior of the user. To test the
feasibility of recruiting a sample of family members to
assess changes in symptoms of stress over time in a con-
firmatory trial (either associated with the social interven-
tion or not), we aim to recruit one family member per
patient entered into the trial at baseline and to follow the
sample up at 3 and 12-months post-intervention.
The overall aim of this early phase trial therefore is to
implement, observe and assess the efficacy of a social-
network intervention (B-SBNT) for both OST patients
and their social network members. The trial aims to
evaluate the feasibility of training NHS clinicians to de-
liver B-SBNT, and to assess the feasibility of recruiting and
retaining patients engaged in drug treatment services to the
trial. Another aim is to evaluate the feasibility of measuring
changes in the health and functioning of family members
before and after a psychosocial intervention.
This early phase trial will test the hypothesis that
B-SBNT is more effective than a case management inter-
vention of similar intensity or treatment as usual in
reducing illicit heroin use 3 and 12 months after treat-
ment in patients receiving OST.
In addition, an attempt will be made to recruit one
family member for each participant in the trial. An im-
portant aim of this part of the study is to establish the
feasibility of recruitment of family members for a future
confirmatory trial. The family members recruited may or
may not be involved in the B-SBNT intervention at a
later stage, but will all be invited to undergo an assess-
ment of levels of stress and associated coping behaviors
with the intention of testing whether those participants
receiving the network intervention show greater reduc-
tions in symptoms.
Finally, qualitative interviews will be conducted with
those receiving as well as those delivering B-SBNT. For
patients the focus will be on the level of satisfaction with
the treatment, the perceived process of change and the
helpful aspects of the therapeutic process. For therapists
the focus will be on the experience of delivering B-
SBNT.Method
Study design
This study is an early phase, two site randomized con-
trolled trial comparing the impact of B-SBNT, Personal
Goal Setting (PGS), and treatment as usual (TAU) for
patients receiving OST. The trial will be conducted
within two community drug treatment teams in two UK
regions: Solihull in the West Midlands and Leicester in
the East Midlands. Figure 1 shows a flow diagram for
the trial, consistent with the Consolidated Standards of
Reporting Trials 2010 statement [26].Intervention
Participants will be randomized to receive one of three
treatment interventions: B-SBNT plus TAU, PGS plus
TAU, or a TAU control condition. Therefore, partici-
pants allocated to either of the first two groups will re-
ceive an active intervention as an adjunct to usual care
provided in the service, delivered by a different therapist
to the participant’s usual key-worker.
Brief Social Behavior and Network Therapy
Participants randomized to receive B-SBNT will be of-
fered four 50-minute B-SBNT sessions over a maximum
of 6 weeks. The treatment manual will combine the
most effective components of the SBNT intervention
from earlier studies [24] with elements of node-link
mapping to facilitate the training and delivery of the
intervention. The treatment will involve working with
the patient to draw a ‘network diagram’ during the first
session to identify potential social support for change
that could be drawn upon during the remaining sessions.
Following this, potential supportive network members
identified by the participant will be approached and in-
vited to take part in treatment sessions to enhance the
social support for change in drug use. The therapist will
use elements of communication skill development, cop-
ing behaviors and the development of joint activities to
support the process, with the ultimate aim of building a
network-supported relapse management plan.
Personal Goal Setting
Participants randomized to receive PGS will be offered
four 50- minute sessions over a period of 6 weeks. In
common with the B-SBNT intervention, therapy will be
delivered according to a purpose designed manual [27].
The PGS condition is designed to control for the inten-
sity of the treatment as well as the process and experi-
ence of receiving an intervention from a different
therapist to the one delivering the routine care. This
intervention will be based on the principles of node-link
mapping [28] and will include a review of the partici-
pant’s current situation and future aspirations, the devel-
opment of SMART (Specific, Measurable, Agreed-upon,
Realistic, Time-limited) goals, and monitoring and feed-
back on progress in achieving these goals.
Treatment as usual
Participants randomized to receive TAU will continue to
receive usual care with no additional therapy sessions.
The participating treatment services do not specify a
particular therapeutic style for working with patients,
and clinicians do not follow a treatment manual. They
are encouraged to use a variety of techniques, and some
will have been exposed to the goal setting and SBNT
techniques as part of their continuing professional
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few published studies describing routine treatment in
OST services in Birmingham [29]. Meetings with pa-
tients occurred between weekly and fortnightly, and
lasted an average of 45 minutes. Session activities fell
into four broad categories, each delivered in similar
amounts: case management, signposting of other ser-
vices, structured psychosocial interventions, and other
activities (for example, medication issues). We therefore
anticipate that TAU will consist of interventions that are
both less structured and less frequent than the two
active treatments under test.
Prior to the commencement of the trial the elements
that comprise ‘standard treatment’ in drug services at
both project sites will be evaluated based on the meth-
odology of previous research [29]. Ten clinical cases will
be selected at random from each site. Electronic dataFigure 1 Flow diagram of the study design.will be screened for the preceding 6-week period to de-
termine the quantity and frequency of drug treatment
sessions. Short unstructured interviews will then be
conducted with each key-worker to identify the content
of each treatment session.
Treatment monitoring and fidelity
To ensure that B-SBNT and PGS are delivered with suf-
ficient fidelity and integrity, all trial therapists will be re-
quired to participate in monthly supervision meetings
with members of the research team. Each therapeutic
session with the therapist will be audio recorded, and a
number of these recordings will be randomly selected
for assessment of the fidelity of the intervention delivery
by members of the research team using the UKATT
Process Rating Scale [30]. This scale was developed as
part of the UKATT and provides a checklist to ensure
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delivered.
The project steering group will be convened at 3-
month intervals, involving the principal investigators,
researchers and service user representatives. An inde-
pendent expert in the field of addiction will review the
data at 6-monthly intervals.
Staff recruitment and training
This study aims to test the feasibility of training NHS
staff to deliver a social network intervention. Therefore,
clinical staff will be asked to volunteer to participate in
the study with no attempt made to randomly select ther-
apists. A minimum of two clinicians per treatment
condition is required at each project site, but more staff
will be trained if available. Training will follow the for-
mat adopted in previous pilot work in this area [23].
Each active intervention will be delivered according to
a purpose-designed treatment manual. The treatment
manual for B-SBNT will be based on a manual from pre-
vious research [23] adapted for a four-session format.
The PGS intervention will follow the manual developed
as part of the National Treatment Agency Routes to
Recovery initiative [27]. There will be an initial 1 day
training session to introduce staff to the key concepts
and procedures involved in each treatment intervention,
and all staff in the B-SBNT condition will be required to
pilot the methods with one clinical case prior to the
commencement of the trial. The trial will only com-
mence once it has been established that B-SBNT is be-
ing delivered with sufficient fidelity, and supervision will
be provided for both active treatment conditions on a
monthly basis.
Participant recruitment and randomization
Four entry criteria must be met for inclusion in the
study: the patient must be 18 years or older; the patient
must have been receiving OST (with either methadone
or buprenorphine) continuously for a period of at least
12 months; the patient must report use of heroin on at
least 1 day in the preceding 28 days; and the patient
must give informed consent to participation.
There will be three exclusion criteria: the patient has
refused to allow their anonymized data to be sent to the
National Drug Treatment Monitoring Service, thus
preventing initial screening (see below); the patient re-
fuses to give informed consent to participation in the
study; and the patient has a severe co-morbid mental or
physical health issue that prevents them participating in
treatment sessions.
All patients receiving treatment from a specialist sub-
stance misuse treatment service in England are asked to
complete the Treatment Outcome Profile every 3 to 6
months [31], which includes questions about use of illicitopiates. These data are stored as part of the patient’s
electronic record along with details of length of time in
treatment, unless the patient has refused consent to
share this information. These data will be interrogated
by the research team every 6 weeks to identify potential
participants that meet the study inclusion criteria. A list
of patients meeting the criteria will be given to clinical
staff in each participating team, and clinicians asked to
approach the patients about the study at their next
routine clinical appointment. The patient’s normal key
worker will therefore provide an initial overview of the
project and written information about the study. If the
patient expresses an interest in taking part they will then
be contacted by a member of the research team who will
explain the study in more detail and invite them to sign
a written consent form. Patients will be randomized and
allocated to treatment intervention following completion
of the baseline interview. A dynamic randomization al-
gorithm will be used, minimizing differences in the
numbers allocated to each experimental group [32]. As
this is an open trial, randomization will not be stratified
by investigational site as this would not be properly
concealed, and will be done using a secure, remote
randomization service independent of the research team.Assessments
Assessment will take place at baseline (prior to treat-
ment randomization), and at 3 and 12 months following
baseline assessment. Socio-demographic information
(age, sex, ethnicity, employment status and living situ-
ation) will be collected at baseline only, but all other
measures will be administered at all 3 time points.Illicit drug use An instant result urine toxicology
test screening for metabolites of opiates will provide
an objective measure of illicit drug use. This will
be supplemented by an interview using sections of
the Maudsley Addiction Profile (MAP) [33]. Section
B records the number of days that the participant has
used heroin, cocaine, benzodiazepines and alcohol in the
past 28 days, and the average amount of use of each
drug on a using day. Section C captures the number of
days that the participant has injected drugs in the past
28 days [33]. Section E records the number of days of
paid work and the amount of acquisitive crime commit-
ted in past 28 days [33]. In addition, the Leeds
Dependence Questionnaire [34] will serve as a diagnos-
tic measure of the severity of dependence and as a
treatment outcome measure that works with abstinent
patients. It consists of 10 questions that are summed to
compute a maximum score of 30, with a higher score
denoting more severe dependence.
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Outcome in Routine Evaluation scale [35] is a 34-item
self-complete questionnaire that gives a measure of
psychological morbidity across four domains: (a) well-
being (4 items); (b) symptoms (12 items - depression ×
4, anxiety × 4, trauma × 2, physical × 2); (c) functioning
(12 items - general × 4, social × 4, and close × 4); and
risk (6 items - to self × 4 or to others × 2). The Social
Satisfaction Questionnaire [36] measures change in so-
cial problems. It is an eight-item self-complete question-
naire with a maximum score of 24, where higher scores
represent greater satisfaction with housing, finances, and
relationships.
Motivation to Change Behaviour The Readiness to
Change Questionnaire - Treatment Version [37] is a 15-
item questionnaire, based on Prochaska and DiClemente’s
stages of change model [38], that assigns drug users to
Precontemplation, Contemplation, and Action stages.
Social Network Composition and Support The Im-
portant People Drug and Alcohol Interview [14] is a
researcher-administered adaption of the Important People
and Activities measure that incorporates questions about
substance abuse. Respondents are asked to provide the
first name and relationship of up to 10 members of their
social network who have been important to them in the
last 3 months. For each network member identified, the
respondent rates frequency of contact, how important the
person is to them, the extent to which the person was
generally supportive of them, substance use status, fre-
quency of substance use, how this person has reacted to
their substance use, and how this person has felt about
them coming for treatment. The Interpersonal Support
Evaluation List [39] consists of a list of 40 statements
concerning the perceived availability of potential social re-
sources. Items each fall into four 10-item subscales: tan-
gible support, appraisal support, self-esteem support,
belonging support. Each is scored between 0 and 30, with
a higher score indicating greater support.
Therapeutic engagement The Engagement section of
the Client Evaluation of Self and Treatment [40] is a
36-item self-completion questionnaire. Each item is
scored between 1 and 5, yielding four sub-scale scores
representing treatment participation, treatment satisfac-
tion, counseling rapport, and peer support.
Family member assessment
Each participant recruited into the trial will be asked to
nominate a family member to be approached to take
part in a short telephone interview at baseline, 3 and 12
months. Symptoms of stress experienced by the family
member, coping behaviors used and the impact of theaddiction problem on the family member will be
assessed using a validated set of standardized question-
naire measures [41]. The Family Member Impact scale is
a 16-item questionnaire designed to assess the extent of
harmful impact that a family member perceives the
relative’s drinking or drug-taking to have on them or the
whole family over the previous 3-month period. Re-
sponse options for each individual item (‘not at all’, ‘once
or twice’, ‘sometimes’ and ‘often’) are scored 0, 1, 2 and 3,
respectively. The Symptom Rating Test measures
physical and psychological ill health in the general popu-
lation. It is brief and easy to complete. Respondents are
asked to indicate whether they have experienced each of
30 symptoms in the past 3 months using response
options ‘never’, ‘sometimes’ or ‘often’ (scored 0, 1 and 2,
respectively). The Coping Questionnaire measures 30
coping actions over the previous 3-month period.
Respondents are given four response options for each
item: ‘no’, ‘once or twice’, ‘sometimes’ and ‘often’, scored 0,
1, 2 and 3, respectively. Previous research suggests the
presence of three factors (tolerant, engaged and with-
drawal coping). Each factor is scored separately as a sub-
scale and a total score is calculated by adding the three
factor scores.
Qualitative assessment
A small number of participants randomized to receive
B-SBNT (n = 10), family members of patients receiving
B-SBNT (n = 10) and therapists trained in B-SBNT (n = 6)
will be asked to participate in a short semi-structured
qualitative interview with the aim of establishing the
level of satisfaction with the treatment, the perceived
process of change and the helpful aspects of the thera-
peutic process. In the case of therapists, the interviews
will also assess how B-SBNT differs from standard
treatment.
Economic evaluation
The economic evaluation will be conducted from a soci-
etal perspective, incorporating the widest measurement
of costs and outcomes as possible. The base-case ana-
lysis will estimate the incremental cost-effectiveness of
B-SBNT versus the two other treatment conditions using
the primary outcome of abstinence of heroin. Further
analyses will incorporate additional outcomes measured
from the perspective of the patients and network mem-
bers and will include assessment of ‘capability wellbeing’
as measured by the Investigating Choice Experiments
Capability measure for Adults (ICECAP-A) [42] and
health status as measured by the EQ-5D [43] at baseline,
3 months and 12 months. Health service and criminal
justice service resource use will be measured using the
Client Service Receipt Inventory [44], and will include
number of general practitioner visits, outpatient and
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vices, criminal justice service costs and medication use.
Unit costs will be obtained from standard sources.
Sample size
As this is an early phase study, a formal sample size cal-
culation is not appropriate. A total of 120 participants
will be recruited to the trial (n = 40 per treatment condi-
tion). If the proportion of patients that stop taking her-
oin in the B-SBNT group is 0.3 we can then produce an
approximate 95% confidence interval of 0.18 to 0.44 for
this estimate; if the proportion is found to be 0.1, an ap-
proximate 95% confidence interval will be 0.01 to 0.19,
showing reasonable precision.
Data analysis
Trial outcome analysis
Data will be analyzed according to the intention-to-treat
principle; all randomized participants will be included in
the analysis irrespective of whether or not they stayed in
the trial, with missing data treated as failing to achieve
reduction. The primary outcome measure will be the
number of days in the preceding 4 weeks that the
participant has used heroin. The primary analyses will
compare B-SBNT with PGS and TAU, and subjects will
be analyzed using a generalized mixed model, including
experimental group as an explanatory classification vari-
able. The therapists will be included as random effects
[45]. In supportive analyses we will examine sequential
measurements of heroin use over 28-day periods as
repeated measures, using appropriate error structures,
including a measure of patient adherence to randomized
therapy over time. Analysis of continuous secondary
outcomes will be conducted using analogous statistical
models, including changes in level of drug-related prob-
lems (such as injecting drug use, criminal activity, and
psychological symptoms), severity of drug dependence,
motivation for drug abstinence, level of social satisfac-
tion, and level of therapeutic engagement. A further im-
portant research outcome will be changes in social
network structure and function, and level of general
social support. The major analyses will be pre-specified in
a statistical analysis plan completed prior to database lock.
Analyses will be conducted in SAS 9.2 or above (SAS
Institute Inc., Cary, NC, USA; www.sas.com/software/sas9;
accessed 11/07/13)
Qualitative analysis
In line with our previous work involving qualitative
evaluation of SBNT [46], interviews will be recorded and
transcribed verbatim for analysis. Thematic analysis will
be used to analyze the data, and the findings will be
presented to a selection of the original participants to
check the validity of the resulting interpretation [47].Economic analysis
The economic analyses will focus on logistical issues
such as the acceptability, feasibility and reliability of the
data collection instruments in this trial population. In-
formation will be collected on length of time taken to
complete each instrument, analysis of missing responses
and exploration of psychometric properties. Descriptive
statistics will be computed for the EQ-5D and the
ICECAP-A, and the within-individual difference in mean
quality-of-life scores will be tested. The evaluation will
be conducted from both a healthcare and a societal
perspective. The analyses will be a within-trial cost-
effectiveness analysis based on the primary outcome of
‘abstinence from heroin’ (for example, the difference in
primary outcome between the intervention arm and the
other two arms of the trial). A secondary analysis will be
a cost-utility analysis using quality-adjusted life years as
the outcome. A decision-tree model [48] will be used
that will adopt an incremental approach and focus on
the differences in cost and outcomes between the trial
arms. Appropriate one-way and multi-way deterministic
sensitivity analysis will be carried out to test the robust-
ness of the results [49]. The choice of variables to assess
as part of the sensitivity analysis will be confirmed when
the data collection is complete but will focus on the
modeling variables which are the most uncertain and
for which there is the greatest amount of sampling
variability.
Ethics
This study has received approval from the National
Research Ethics Committee: The Black Country (REC
number: 12/WM/0046; approved 08/05/2012).
Discussion
The National Institute for Health and Clinical Excellence
has highlighted the evidence for psychosocial treatments
for heroin dependence [50], and family/social network
interventions are promising for two reasons: (1) by in-
volving family and friends in the treatment process there
are opportunities for generalization of the effects beyond
an episode of professional treatment; and (2) treatment
may reduce the considerable physical and psychological
health burden of drug misuse on family and friends.
The B-SBNT intervention has been specifically
adapted to make it more suitable for use within UK drug
treatment services by using the elements found to be
most important in the process of drug-use change [24].
This study aims to establish the feasibility of delivering a
social network-based treatment for patients receiving
OST within NHS drug services, as well as the impact of
the intervention on both short (3 months) and longer-
term outcome (12 months) for patients and their family
members. Evaluation of the efficacy of B-SBNT will
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the trial will involve a comprehensive economic
evaluation.
This study will recruit and follow-up family members
of patients in UK NHS drug treatment within a random-
ized controlled trial design, and the results will inform
the feasibility of recruitment of family members in a lar-
ger confirmatory trial with the potential to help further
our understanding of the impact of drug use on family
members, as well as the benefits to family members
from inclusion in the drug treatment process.
The study will quantify various elements of uncertainty
around the delivery of social network interventions in
the OST population, and the measurement of its effect-
iveness: the feasibility of recruiting and training staff
(that is, number willing to be trained, levels of attend-
ance at training and supervision sessions, degree of
adherence to the treatment manuals, level of staff satis-
faction with the training and the interventions); the
feasibility of recruiting patients (that is, number wishing
to participate, attendance at assessment sessions, attend-
ance at intervention appointments, client satisfaction
with B-SBNT); the feasibility of recruiting network
members into the treatment process (that is, numbers
agreeing to participate, attendance at appointments, level
of acceptance of B-SBNT treatment); the feasibility of
recruiting family members to evaluate the impact of the
intervention on their health (that is, number of family
members recruited and interviewed, acceptance of the
measures of symptoms and coping); and the feasibility of
employing the chosen research procedures in clinical
services (that is, recruitment methods, including giving
information and obtaining consent), randomization,
intervention delivery and outcome measurement).
In order for this study to lead to a definitive trial it will
need to provide an indication of positive change in the
main outcome measure for the social network interven-
tion. However, it will also be important to know the stand-
ard deviation of this measure to determine if the required
sample size for a definitive trial is realistic. The study will
tell us whether participating centers are likely to recruit a
sufficient number of participants to deliver a full trial
within a reasonable timescale.
Research demonstrates significantly better outcomes
for drug-using individuals, such as reduced risk of drug
relapse and better response to treatment, when there is
positive social support for change [10-14]. However, at
present no available model exists to implement a family
and social intervention in routine practice in the UK
NHS drug treatment system. Furthermore, there is very
limited knowledge of the composition and potential
availability of supportive social networks to people in
drug treatment services. This study is an important step
in the development of evidence and aims to addressthese gaps in the literature. It is hoped that the results of
the study will help to inform future service provision in
drug treatment services for patients receiving OST.
Trial status
The trial is currently in the recruitment phase.
Abbreviations
B-SBNT: Brief Social Behavior and Network Therapy; EQ-5D: European Quality
of Life; ICECAP-A,; MAP: Maudsley Addiction Profile; NHS: National Health
Service; NTA: National Treatment Agency; OST: opiate substitution therapy;
PGS: Personal Goal Setting; SBNT: Social Behavior and Network Therapy;
TAU: treatment as usual; UKATT: UK Alcohol Treatment Trial.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ED is the chief investigator for the project. ED, AC and JLS drafted the
manuscript. ED, AC, MC, SG, AB, EF and NF contributed to the design of the
study. JLS coordinated the implementation of the project. JLS, DB and CP
were involved in the collection of data. All authors read and approved the
final manuscript.
Acknowledgements
This paper presents independent research funded by the National Institute
for Health Research (NIHR) under its Research for Patient Benefit (RfPB)
Programme (Grant Reference Number PB-PG-0610-22392). The views
expressed are those of the authors and not necessarily those of the NHS,
the NIHR or the Department of Health.
Author details
1Birmingham & Solihull Mental Health Foundation Trust, Research &
Innovation Department, Radclyffe House, 66-68 Hagley Road, Birmingham
B16 8PF, UK. 2Addictions Department, National Addiction Centre, Addiction
Sciences Building, 4 Windsor Walk, Denmark Hill, London SE5 8AF, UK.
3School of Psychology, The University of Birmingham, Birmingham B15 2TT,
UK. 4Leicester City Drug & Alcohol Service, Paget House, 2 West Street,
Leicester LE1 6XP, UK. 5Health Economics, School of Health and Population
Sciences, College of Medical and Dental Sciences, University of Birmingham,
Edgbaston, Birmingham B15 2TT, UK. 6Department of Primary Care and
Population Health, Upper Third Floor, UCL Medical School (Royal Free
Campus), Rowland Hill Street, London NW3 2PF, UK.
Received: 28 February 2013 Accepted: 6 August 2013
Published: 19 August 2013
References
1. Davies C, English L, Stewart C, Lodwick A, McVeigh J, Bellis MA: United
Kingdom Drug Situation: Annual Report to the European Monitoring Centre for
Drugs and Drug Addiction (EMCDDA) 2011. London: UK Focal Point at the
Department of Health; 2011.
2. Best D, George S, Day E: The development of the drug treatment system
in England. In Clinical Topics in Addiction. Edited by Day E. London:
RCPsych; 2007:14–28.
3. HM Government: Drug Strategy 2010. Reducing Demand, Restricting Supply,
Building Recovery: Supporting People to Live a Drug Free Life. London: Home
Office; 2010:2010.
4. McKeganey N, Bloor M, Robertson M, Neale J, MacDougall J: Abstinence
and drug abuse treatment: results from the drug outcome research in
Scotland study. Drugs: Education, Prevention and Policy 2006, 13:537–550.
5. Drummond DC, Kouimtsidis C, Reynolds M, Russell I, Godfrey C, McCusker
M, Coulton S, Parrott S, Davis P, Tarrier N, Turkington D, Sell L, Merrill J,
Williams H, Abou-Saleh M, Ghodse H, Porter S, Daw R, Fyles N, Keating S,
Moloney A, Pryce K, Mehdikhani M, Barnaby B, Leach J, Ruben S, UKCBTMM
Project Group, UKCBTMM Research Team: The Effectiveness and Cost
Effectiveness of Cognitive Behaviour Therapy for Opiate Misusers in Methadone
Maintenance Treatment: a Multicentre Randomised Controlled Trial
(UKCBTMM). Final Report to the Department of Health Research and
Development Directorate. London: Department of Health; 2004.
Day et al. Trials 2013, 14:264 Page 9 of 9
http://www.trialsjournal.com/content/14/1/2646. Best D, Hernando R, Gossop M, Sidwell C, Strang J: Getting by with a little
help from your friends. The impact of peer networks on criminality in a
cohort of treatment-seeking drug users. Addictive Behaviours 2003,
28:597–603.
7. Gogineni A, Stein M, Friedmann PD: Social relationships and intravenous
drug use among methadone maintenance patients. Drug Alcohol Depend
2001, 64:47–53.
8. Latkin C, Mandell W, Oziemkowska M, Celentano D, Vlahov D, Ensminger M,
Knowlton A: Using social network analysis to study patterns of drug use
among urban drug users at high risk for HIV/AIDS. Drug Alcohol Depend
1995, 38:1–9.
9. Schroeder JR, Latkin CA, Hoover DR, Curry AD, Knowlton AR, Celentano DD: Illicit
drug use in one’s social network and in one’s neighbourhood predicts
individual heroin and cocaine use. Ann Epidemiol 2001, 11:389–394.
10. Cohen S, Lichtenstein E: Partner behaviours that support quitting
smoking. J Consult Clin Psychol 1990, 58:304–309.
11. Goehl L, Nunes E, Quitkin F, Hilton I: Social networks and methadone
treatment outcome: the costs and benefits of social ties. Am J Drug
Alcohol Abuse 1993, 19:251–262.
12. Havassy BE, Wasserman DA, Hall SM: Social relationships and abstinence from
cocaine in an American treatment sample. Addiction 1995, 90:699–710.
13. Wasserman DA, Stewart AL, Delucchi KL: Social support and abstinence
from opiates and cocaine during opioid maintenance treatment.
Drug Alcohol Depend 2001, 65:65–75.
14. Zywiak WH, Neighbors CJ, Martin RA, Johnson JE, Eaton CA, Rohsenow DJ:
The important people drug and alcohol interview: psychometric
properties, predictive validity, and implications for treatment. J Subst
Abuse Treat 2009, 36:321–330.
15. Copello A, Templeton L, Powell J: Adult Family Members and Carers of
Dependent Drug Users: Prevalence, Social Cost, Resource Savings and
Treatment Responses. London: UK Drug Policy Commission; 2009.
16. National Treatment Agency for Substance Misuse: NTA Policy on Involvement
of Users and Family Members. London: NTA; 2008.
17. The Centre for Social Justice: Green Paper on Criminal Justice and Addiction.
London: The Centre for Social Justice; 2010.
18. National Treatment Agency for Substance Misuse: NTA Business Plan 2010–11.
London: NTA; 2010.
19. The Betty Ford Institute Consensus Panel:What is recovery? A working
definition from the Betty Ford Institute. J Subst Abuse Treat 2007, 33:221–228.
20. Copello A, Orford J, Hodgson R, Tober G, Barrett C: Social behaviour and
network therapy - basic principles and early experiences. Addictive
Behaviours 2002, 27:345–366.
21. UKATT Research Team: Effectiveness of treatment for alcohol problems:
findings of the randomised UK alcohol treatment trial (UKATT). BMJ 2005,
331:541–544.
22. UKATT Research Team: Cost effectiveness of treatment for alcohol
problems: findings of the randomised UK alcohol treatment trial
(UKATT). BMJ 2005, 331:544–548.
23. Copello A, Williamson E, Orford J, Day E: Implementing and evaluating
social behaviour and network therapy in drug treatment practice in the
UK: a feasibility study. Addict Behav 2006, 31:802–810.
24. Dale V, Coulton S, Godfrey C, Copello A, Hodgson R, Heather N, Orford J,
Raistrick D, Slegg G, Tober G, on behalf of the UKATT Research Team:
Exploring treatment attendance and its relationship to outcome in a
randomized controlled trial of treatment for alcohol problems:
secondary analysis of the UK alcohol treatment trial (UKATT). Alcohol
Alcohol 2011, 46:592–599.
25. Ray GT, Mertens JR, Weisner C: Family members of people with alcohol or
drug dependence: health problems and medical cost compared to
family members of people with diabetes and asthma. Addiction 2009,
104:203–214.
26. Schulz KF, Altman DG, Moher D, Group ftC: CONSORT 2010 Statement:
updated guidelines for reporting parallel group randomised trials.
BMJ 2010, 340:c332.
27. Day E, Best D, Bartholomew NG, Dansereau DF, Simpson DD: The BTEI Care
Planning Manual: Mapping Achievable Goals. In Routes to Recovery. London:
National Treatment Agency for Substance Misuse; 2009.
28. Dansereau DF, Simpson DD: A picture is worth a thousand words: the
case for graphic representations. Professional Psychology: Research and
Practice 2009, 40:104–110.29. Best D, Day E, Morgan B, Oza T, Copello A, Gossop M: What treatment
means in practice: an analysis of the delivery of evidence-based
structured interventions in criminal justice drug treatment services in
Birmingham. England Addiction Research and Theory 2009, 17:678–687.
30. Tober G, Clyne W, Finnegan O, Farrin A, Russell I, UKATT Research Team:
Validation of a scale for rating the delivery of psycho-social treatments
for alcohol dependence and misuse: The UKATT Process Rating Scale
(PRS). Alcohol & Alcoholism 2008, 43:675–682.
31. Marsden J, Farrell M, Bradbury C, Dale-Perera A, Eastwood B, Roxborough M,
Taylor S: Development of the treatment outcomes profile. Addiction 2008,
103:1450–1460.
32. Pocock SJ: Clinical Trials: A Practical Approach. Chichester: John Wiley & Sons; 1983.
33. Marsden J, Gossop M, Stewart D, Best D, Farrell M, Strang J: The Maudsley
Addiction Profile: Development and User Manual. London: National Addiction
Centre/Institute of Psychiatry; 1998.
34. Raistrick D, Bradshaw J, Tober G, Weiner J, Allison J, Healey C: Development
of the Leeds Dependence Questionnaire (LDQ): a questionnaire to
measure alcohol and opiate dependence in the context of a treatment
evaluation package. Addiction 1994, 89:563–572.
35. Evans C, Connell J, Barkham M, Margison F, McGrath G, Mellor-Clark J, Audin
K: Towards a standardized brief outcome measure: psychometric
properties and utility of the CORE-OM. Br J Psychiat 2002, 180:51–60.
36. Raistrick D, Tober G, Heather N, Clark JA: Validation of the Social
Satisfaction Questionnaire for outcome evaluation in substance use
disorders. Psychiatric Bulletin 2007, 31:333–336.
37. Heather N, Luce A, Peck D, Dunbar B, James I: Development of a treatment
version of the Readiness to Change Questionnaire. Addiction Research 1999,
7:63–83.
38. Prochaska JO, DiClemente CC: Transtheoretical therapy: toward a more
integrative model of change. Psychotherapy: Theory Research and Practice
1982, 19:276–288.
39. Cohen S, Mermelstein R, Kamarck T, Hoberman HM: Measuring the
functional components of social support. In Measuring the Functional
Components of Social Support. Edited by Sarason IG, Sarason BR. London:
Springer; 1985:73–94.
40. Joe GW, Broome KM, Rowan-Szal GA, Simpson DD: Measuring patient
attributes and engagement in treatment. J Subst Abuse Treat 2002,
22:183–196.
41. Orford J, Templeton L, Velleman R, Copello A: Family members of relatives
with alcohol, drug and gambling problems: a set of standardized
questionnaires for assessing stress, coping and strain. Addiction 2005,
100:1611–1624.
42. Al-Janabi H, Flynn TN, Coast J: Development of a self-report measure of
capability wellbeing for adults: the ICECAP-A. Qual Life Res 2011, 21:167–176.
43. The EuroQol Group: EuroQol - a new facility for the measurement of
health-related quality of life. Health Policy 1990, 16:199–208.
44. Beecham J, Knapp M: Costing psychiatric interventions. In Measuring
Mental Health Needs. Edited by Thornicroft G, Brewin C, Wing J. London:
Gaskell; 1992:163–183.
45. SAS Institute Inc: Chapter 6: Introduction to mixed modelling procedures.
In SAS/STAT 92 User’s Guide (second Edition). Cary, NC: SAS Institute Inc;
2009:127–140.
46. Williamson E, Smith M, Orford J, Copello A, Day E: Social behaviour and
network therapy for drug problems: evidence of benefits and
challenges. Addictive Disorders and Their Treatment 2007, 6:167–179.
47. Braun V, Clarke V: Using thematic analysis in psychology. Qualitative
Research in Psychology 2006, 3:77–101.
48. Briggs A, Sculpher M, Claxton C: Decision Modelling for Economic Evaluation.
Oxford: Oxford University Press; 2006.
49. Walker D, Fox-Rushby J: Allowing for uncertainty in economic evaluations:
qualitative sensitivity analysis. Health Policy Plan 2001, 16:435–443.
50. National Collaborating Centre for Mental Health: Drug Misuse: Psychosocial
Interventions. London: British Psychological Society & The Royal College of
Psychiatrists; 2008.
doi:10.1186/1745-6215-14-264
Cite this article as: Day et al.: Pilot study of a social network
intervention for heroin users in opiate substitution treatment: study
protocol for a randomized controlled trial. Trials 2013 14:264.
